A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine

CHA Vaccine Institute

Status and phase: Completed; Phase 2; Phase 1

Conditions: Hepatitis B, Chronic

Treatments: Biological: CVI-HBV-002

Study type: Interventional

Funder types: Industry

Identifiers

NCT02693652

CVI-HBV-002-CT1301

Details and patient eligibility

About

A single center, open labeled phase I/IIa study to evaluate safety, tolerability and efficacy of a therapeutic hepatitis B vaccine in oral antiviral drug-treated chronic hepatitis B virus carriers

Full description

• Objectives: To explore the appropriate dose of a therapeutic hepatitis B vaccine through the evaluation of safety, tolerability, and efficacy
• Subjects: Chronic hepatitis B carrier with normal ALT range
• Study hypothesis: The immune tolerance break and strong immune responses in the chronic hepatitis B carrier could be achieved with therapeutic hepatitis B vaccine containing novel adjuvant

Enrollment: 53 patients

Sex: All

Ages: 19 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adult between 19 to 60 years of age
2. Chronic hepatitis B carriers (HBsAg positive over 6 months)
3. HBeAg positive patient, or patient who had lost HBeAg during Antiviral drug treatment
4. Antiviral drug treated patient reducing the HBV DNA level below 2000 IU/mL measured by COBAS TaqManM HBV Test (Duration of drug administration should be over 6 months and no limitation on the type of antiviral drug)
5. Patient has low ALT than 1.1 fold of upper limit of normal ALT level at screening
6. Patient is able to provide written informed consent by oneself or legal representative

Exclusion criteria

1. Patient has liver diseases except chronic hepatitis B (i.e. hematochromatosis, alcoholic liver disease, nonalcoholic fatty liver disease, alpha-1 antitrypsin deficiency etc.)

2. Patient has one or more test results and symptoms at the screening

   • ALT > upper limit of normal level X 1.1
   • Total bilirubin > upper limit of normal
   • Prothrombin time > Over 3 second than normal
   • Serum Albumin < 30 g/L (3 g/dL)
   • Patient has history of ascites, yellow jaundice, variceal hemorrhage, hepatic encephalopathy, or liver failure
   • Liver FibroScan > F3 (F0: no fibrosis, F1: portal fibrosis, F2: periportal fibrosis, F3: septal fibrosis, F4: cirrhosis)

3. Patient has one or more test results at the screening

   • Hemoglobin < 9.0 g/dL
   • Absolute neutrophil count (ANC) < 1.5 x 109 /L (1500 /mm3)
   • Platelet count < 100 x 109 /L (100 x 103 /mm3)
   • Serum creatinine > 1.5 mg/dL
   • Serum amylase > 2 x ULN and Lipase > 2 x ULN

4. Patient has history of Interferon treatment

5. Patient is pregnant or breastfeeding or intending to become pregnant during the study

6. Patient has active microbial, viral, or fungal infections in need of systemic treatment

7. Alpha-fetoprotein (AFP) > 50 ng/mL or Hepatocellular Carcinoma (HCC) patient

8. Among the patients treated with immunosuppressive drug within 6 months before screening, suspected case of the declined immunity in the opinion of the investigator

9. Patient had long term systemic treatment (more than 14 days consecutively) of high dose (over 20 mg of prednisolone or equivalent dose*) corticosteroid (Decision to participate of patient who had local treatment of corticosteroid is allowed in the opinion of the investigator)

   *equivalent to cortisone 125 mg, hydrocortisone 100 mg, prednisone 20 mg, methylprednisolone 16 mg, triamcinolone 16 mg, dexamethasone 3 mg, or betamethasone 2.4 mg

10. Patient diagnosed with a malignant tumor within 5 years before screening or relapsed patient (Benign tumor patient is able to participate in this study at the discretion of the investigator)

11. Patient has history of organ transplantation

12. Patient has serious disease judged by investigator such as heart failure, renal failure, and pancreatitis

13. Patient has history of serious heart disease (NYHA Functional Class III or IV heart failure, myocardial infarction within 6 months, treatment required ventricular tachyarrhythmias, or unstable angina etc.)

14. Patient has seizure disorder required anticonvulsants treatment

15. Uncontrollable diabetic patient (FBS>130mg/dl, HbA1c>7.5%)

16. Uncontrollable hypertension patient (SBP≥140mmHg 또는 DBP≥90mmHg)

17. HCV, HDV, or HIV patient

18. Patient has a plan to participate in other clinical study, or took part in other clinical study within 1 month before enrollment

19. Patient has hypersensitivity or anaphylactic reaction for components of investigational product or HBV vaccine

20. Patient has continuous drinking (>21 units/week, 1 unit = 10g of pure alcohol) or dependence on alcohol

21. Patient concerned about the decline in daily activity or not able to understand the objectives and methods due to the psychiatric problems

22. Patient has potential to severe febrile or systemic reaction

23. Subject unacceptable in this study under the opinion of the investigator

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

53 participants in 4 patient groups

CVI-HBV-002 (20ug, 3 shots)

Experimental group

Description:

* HBV surface antigen 20ug/dose * Intramuscular injection at 0, 1, 2 month

Treatment:

Biological: CVI-HBV-002

CVI-HBV-002 (20ug, 6 shots)

Experimental group

Description:

* HBV surface antigen 20ug/dose * Intramuscular injection at 0, 1, 2, 3, 4, 5 month

Treatment:

Biological: CVI-HBV-002

CVI-HBV-002 (40ug, 3 shots)

Experimental group

Description:

* HBV surface antigen 40ug/dose * Intramuscular injection at 0, 1, 2 month

Treatment:

Biological: CVI-HBV-002

CVI-HBV-002 (40ug, 6 shots)

Experimental group

Description:

* HBV surface antigen 40ug/dose * Intramuscular injection at 0, 1, 2, 3, 4, 5 month

Treatment:

Biological: CVI-HBV-002